Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent ...
LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global contrast injectors market since 2015 and the market is poised to grow by USD 613.47 million during 2020-2024, progressing at a CAGR of ...
Nanoparticles that exhibit localization to specific organs or to sites of disease via biological mechanisms, such as the RES or the EPR effect, are known as 'passive targeting agents'. One of the ...
According to ARRS' American Journal of Roentgenology (AJR), the selection of oral contrast agent and optimization of bowel preparation for oncologic CT could help avoid potentially severe clinical ...
Although CT is a relatively recent technology, there have been great improvements in the equipment. The early, slow "Step and Scan" machines required long image acquisition times, resulting in a ...
Mason Frazier, M.D., associate professor in the University of Alabama at Birmingham’s Marnix E. Heersink School of Medicine’s Department of Radiology, says contrast imaging is important part of ...
Follows recent FDA clearance to expand the use of compatible contrast agent presentations, adding single-dose vials in addition to Imaging Bulk Package presentations Radiology suites now have the ...
Centargo compatible with Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol) Follows recent FDA clearance to expand the use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback